home Go to Consumers Page
Doctor Site Health
Consumer
1 888 433 4726
  • Doctor
  • Consumer
Facebook Twitter
HAVE A SBH REP CONTACT ME
REGISTER NOW TO GET STARTED

phone

Basket

Request to be contacted


Email address is invalid.
*
*
Doctor Name is required.

Allow only alphanumeric characters
*
*
Doctor Practice is required.

Allow only alphanumeric characters
*
Contact Person is required.
*
Practice Phone Number is required.

Phone number must contain 10 digits.
*
Email address is required.
*
Practice City is required.

Allow only alphanumeric characters
*
Practice State is required.

Allow only alphanumeric characters

Allow only alphanumeric characters

Allow only alphanumeric characters
 
Menu
  • Products
    • Products A-Z
    • Dry Eye
    • Eye & Whole Body Health
      • OcularProtect® Robust Whole Body Formula
      • OcularEssentials® Whole Body Formula
    • Macular Health Concerns
      • MacularProtect Complete® AREDS-Based Formula & Multinutrient
      • MacularProtect® AREDS-Based Formula
    • Omega-3
    • Optic Nerve Health
    • Retinal Circulation
    • Bone & Joint Health
      • BoneProtect
      • JointProtect
  • Faqs
  • Getting Started
  • Practice Resources
  • Science
    • EduFacts Newsletter
    • Nutrient Glossary
    • Product Monographs
    • Educational Links
  • About us
    • Company
    • Advisory Boards
    • Press Releases
    • In The News
    • Events
  • Contact
  • Login
  • View Cart
  • (0)
Facebook Twitter

EduFacts Newsletter

EPA & DHA Linked to Lower AMD Risk at AREDS 2 Start

EPA & DHA Linked to Lower AMD Risk at AREDS 2 Start

ScienceBased Health - Education - EduFacts

EPA & DHA Linked to Lower AMD Risk in AREDS 2 Baseline Data

AREDS 2 Basics

AREDS 2 is a nationwide study to determine whether high dose carotenoids (lutein and zeaxanthin) and omega-3 fatty acids (DHA and EPA) can slow vision loss in people at moderate to high risk for the progression of AMD. The study began in the fall of 2006, and is expected to be completed in 2013.

The 3 interventions arms for the carotenoids and omega-3s are: 1) 10 mg of lutein and 2 mg of zeaxanthin plus placebo; 2) 350 mg of DHA and 650 mg of EPA plus placebo; and 3) a combination of the DHA/EPA and lutein/ zeazanthin. In addition, all participants are offered the original AREDS formula (now considered standard of care) or 3 variations of this formula: (1) no beta-carotene; (2) lower amounts of zinc; and (3) no beta-carotene and lower zinc.

At the Association for Research in Vision and Ophthalmology's meeting in May, researchers presented the baseline demographic and dietary characteristics of AREDS 2 participants, and their associations with AMD (1). They report that people consuming the most DHA or EPA had the lowest rating of AMD severity.

Study Design

Baseline fundus photographs were centrally graded with a standardized protocol using drusen size and pigment characteristics to assign the AREDS 5 level simple scale score of severity. Participants completed a dietary assessment at baseline, and nutrient density values were classified into quintiles. Data were adjusted for age, gender and

Results

Demographic characteristics are shown in Table 1. Dietary DHA and EPA were inversely related to AMD severity score in energy-adjusted comparisons of highest versus lowest quintile intake (p<0.05 for both nutrients, see Table 2). Trend tests on quintile median nutrient values yielded a p-value of <0.01 for both EPA and DHA. The association of lutein and zeaxanthin intake with severity score was in the direction of benefit, but did not achieve statistical significance.

table 1
table 2

Comments

At baseline, AREDS 2 participants had good visual function in their study eye(s). The majority had large drusen and/or pigmentary changes in the retinal pigment epithelium, risk factors for progression to advanced AMD. The authors conclude that those with the highest intake of DHA or EPA were significantly less likely than their peers to have higher AMD severity scores.

References

  1. Chang JR, et al. Demographic and dietary characteristics of the Age-Related Eye Disease Study 2 (AREDS2) participants and their associations with age-related macular degeneration (AMD). ARVO May 2-6, 2010, Ft. Lauderdale, FL, e-Abs 97.
Home  >  General Webpages  >  Resources  >  Edufacts Content  >  EduFacts Scientific Write-ups  >